DME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018

Similar documents
DME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019

J1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) 500 MG $ J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $14.364

MDwise Self-Administered Codes for Medical

Medicare Part B Covered Medications

Drug Name Tier Drug Name Tier

The following are J Code requirements

Injections Requiring Prior Authorization

Subject: Fosnetupitant-Palonosetron (Akynzeo) IV

Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19

MEDICAL POLICY No R10 INFUSION SERVICES & EQUIPMENT

Subject: Palonosetron Hydrochloride (Aloxi )

Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )

Modular Program Report

External Infusion Pumps

Table III: 2019 Medicare Drug Fee Schedule* CY st Quarter Average Sales Price (ASP) Data Plus 6 Percent

MASCC Guidelines for Antiemetic control: An update

A9542 A9543 A9545 A9699 J0120 J0128 J0129 J0130

Drug Use Evaluation: Physician Administered Drugs (PADs)

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

Highmark List of Procedure Codes Requiring NDC Effective 12/01/2017

Guideline Update on Antiemetics

Medicare Part C Medical Coverage Policy

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

MEDICAL MANAGEMENT POLICY

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

Immune Globulin. Prior Authorization

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

High Risk Medications

Injectables/Medications Administered Under the Medical Benefit Authorization NOT Required List Effective 04/01/2017

Guidelines for the Use of Anti-Emetics with Chemotherapy

Drug Class Prior Authorization Criteria Immune Globulins

Committee Approval Date: December 12, 2014 Next Review Date: July 2015

See Important Reminder at the end of this policy for important regulatory and legal information.

Cigna Drug and Biologic Coverage Policy

Medicare Part C Medical Coverage Policy

Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives

Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.

Description The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )

LCD for Nebulizers (L27226)

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List

LCD for Nebulizers (L11488)

Intravenous Immune Globulin (IVIg)

Cost-Motivated Treatment Changes in Medicare Part B:

Managements of Chemotherpay Induded Nausea and Vomiting

Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting

See Important Reminder at the end of this policy for important regulatory and legal information.

Welcome. Coding uidelines Coding Guidelines Coding. Coding Guidelines Coding Guidelines. Contact Us. Edition #1 March 2018

ANTIEMETICS UTILIZATION MANAGEMENT CRITERIA

INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY]

ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY

Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care

Generic (Brand) Strength & Dosage form Fml Limit Cost per Rx Notes 5-HT3 Antagonists

NOTICES DEPARTMENT OF HEALTH

Clinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:

See Important Reminder at the end of this policy for important regulatory and legal information.

Part B payment for drugs in Medicare 0

APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer

Measure Abbreviation: PONV 01 (MIPS 430)

Northern Cancer Alliance

CURRENT DRUG SHORTAGES (through February 22, 2013) CURRENT & ONGOING SHORTAGES CRITICAL SHORTAGES

IMMUNE GLOBULIN (IVIG AND SCIG) Brand Name Generic Name Length of Authorization Bivigam IVIG Per Medical Guidelines Carimune IVIG Per Medical

Billing & Coding Guide

Antiemesis. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version Continue

1 17 ACITRETIN 10MG CAP 20, ,000 14,000 4, ACITRETIN 25MG CAP 50, ,000 35,000 10,000

Product Name Strength Dosage Form Therapeutic Area Dossier Status. Aceclofenac 100mg Film coated Tablets Analgesia-inflammation Approved

Corporate Medical Policy

TennCare Program TN MAC Price Change List As of: 03/30/2017

Clinical Policy: Eltrombopag (Promacta) Reference Number: ERX.SPA.71 Effective Date:

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:

Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients

IHCP banner page INDIANA HEALTH COVERAGE PROGRAMS BR FEBRUARY 16, 2016

Antiemesis. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue

SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders

LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT


CPT Service Description Effective Date

MEDICAL NECESSITY GUIDELINE

A CMS Program Safeguard Contractor. The following list identifies changes to level II Healthcare Common Procedure Coding System (HCPCS) for 2008.

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER

RITUXAN (rituximab and hyaluronidase human)

Clinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:

See Important Reminder at the end of this policy for important regulatory and legal information.

Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site

Our mission is better health care outcomes.

Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting

See Important Reminder at the end of this policy for important regulatory and legal information.

ADULT Updated: September 4, 2018

See Important Reminder at the end of this policy for important regulatory and legal information.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Antiemesis. Version NCCN.org. Continue

Rolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Part B payment for drugs in Medicare 0

Job title: Consultant Pharmacist/Advanced Practice Pharmacist

Emetogenicity level 1. Emetogenicity level 2

Measure Abbreviation: PONV 01 (MIPS 430)

Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients

To help doctors give their patients the best possible care, the American

Modular Program Report

Transcription:

G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.068 J0285 INJECTION, AMPHOTERICIN B 50 MG $32.987 J0287 INJECTION, AMPHOTERICIN B LIPID COMPLEX 10 MG $14.920 J0288 INJECTION, AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX 10 MG TBD* J0289 INJECTION, AMPHOTERICIN B LIPOSOME 10 MG $20.708 J0895 INJECTION, DEFEROXAMINE MESYLATE $8.038 J1170 INJECTION, HYDROMORPHONE UP TO 4 MG $1.573 J1250 INJECTION, DOBUTAMINE HYDROCHLORIDE 250 MG $6.486 J1265 INJECTION, DOPAMINE HCL 40 MG $0.631 J1325 INJECTION, EPOPROSTENOL 0.5 MG $15.566 J1455 INJECTION, FOSCARNET SODIUM 1000 MG $75.172 J1459 INJECTION, IMMUNE GLOBULIN (PRIVIGEN), INTRAVENOUS, NON-LYOPHILIZED (E.G. LIQUID) $38.482 J1555 INJECTION, IMMUNE GLOBULIN (CUVITRU) 100 MG $13.789 J1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) $70.516 J1557 INJECTION, IMMUNE GLOBULIN, (GAMMAPLEX), INTRAVENOUS, NON-LYOPHILIZED (E.G. LIQUID) $40.033 J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $9.831 J1561 INJECTION, IMMUNE GLOBULIN, (GAMUNEX- C/GAMMAKED), NON-LYOPHILIZED (E.G. LIQUID) $40.703 J1561JB INJECTION, IMMUNE GLOBULIN, (GAMUNEX- Same as C/GAMMAKED), NON-LYOPHILIZED (E.G. LIQUID) [JB J1561** modifier indicates drug being administered subcutaneously] J1562 INJECTION, IMMUNE GLOBULIN (VIVAGLOBIN) 100 MG TBD* J1566 INJECTION, IMMUNE GLOBULIN, INTRAVENOUS, LYOPHILIZED (E.G. POWDER), NOT OTHERWISE SPECIFIED $34.417 J1568 INJECTION, IMMUNE GLOBULIN, (OCTAGAM), INTRAVENOUS, NON-LYOPHILIZED (E.G. LIQUID) $35.591 J1569 INJECTION, IMMUNE GLOBULIN, (GAMMAGARD LIQUID), NON-LYOPHILIZED, (E.G. LIQUID) $40.723 J1569JB INJECTION, IMMUNE GLOBULIN, (GAMMAGARD LIQUID), Same as NON-LYOPHILIZED, (E.G. LIQUID) [JB modifier indicates drug J1569** being administered subcutaneously] J1570 INJECTION, GANCICLOVIR SODIUM $67.175 INJECTION, IMMUNE GLOBULIN, J1572 (FLEBOGAMMA/FLEBOGAMMA DIF), INTRAVENOUS, NON- LYOPHILIZED (E.G. LIQUID) $33.654 J1575 INJECTION, IMMUNE GLOBULIN/HYALURONIDASE, 100 MG (HYQVIA) $14.063 J1817 INSULIN FOR ADMINISTRATION THROUGH DME (I.E., 50 UNITS INSULIN PUMP) $10.107 J2175 INJECTION, MEPERIDINE HYDROCHLORIDE 100 MG $4.430 J2260 INJECTION, MILRINONE LACTATE 5 MG $1.595 J2270 INJECTION, MORPHINE SULFATE UP TO 10 MG $2.036 J2274 INJECTION, MORPHINE SULFATE, PRESERVATIVE-FREE 10 MG FOR EPIDURAL OR INTRATHECAL USE $11.493 Copyright 2017 CGS Administrators, LLC. Page 1 of 6 12/272017

J2278 INJECTION, ZICONOTIDE 1 MCG $7.438 J2545 PENTAMIDINE ISETHIONATE, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, 300 MG $117.310 J2920 INJECTION, METHYLPREDNISOLONE SODIUM UP TO 40 MG SUCCINATE $4.346 J2930 INJECTION, METHYLPREDNISOLONE SODIUM UP TO 125 MG SUCCINATE $5.985 J3010 INJECTION, FENTANYL CITRATE 0.1 MG $0.480 J3285 INJECTION, TREPROSTINIL 1 MG $61.237 J7340 CARBIDOPA 5 MG/LEVODOPA 20 MG ENTERAL 100 ML SUSPENSION $213.950 J7500 AZATHIOPRINE, ORAL 50 MG $0.329 J7501 AZATHIOPRINE, PARENTERAL 100 MG TBD* J7502 CYCLOSPORINE, ORAL 100 MG $2.666 J7503 TACROLIMUS, EXTENDED RELEASE, (ENVARSUS XR), 0.25 MG ORAL $1.233 J7504 LYMPHOCYTE IMMUNE GLOBULIN, ANTITHYMOCYTE 250 MG GLOBULIN, EQUINE, PARENTERAL $1,942.780 J7507 TACROLIMUS, IMMEDIATE RELEASE, ORAL 1 MG $0.587 J7508 TACROLIMUS, EXTENDED RELEASE, ORAL 0.1 MG $0.433 J7509 METHYLPREDNISOLONE, ORAL 4 MG $0.378 J7510 PREDNISOLONE, ORAL 5 MG $0.088 J7511 LYMPHOCYTE IMMUNE GLOBULIN, ANTITHYMOCYTE 25 MG GLOBULIN, RABBIT, PARENTERAL $712.202 J7512 PREDNISONE, IMMEDIATE RELEASE OR DELAYED 1 MG RELEASE, ORAL $0.014 J7515 CYCLOSPORINE, ORAL 25 MG $0.751 J7516 CYCLOSPORINE, PARENTERAL 250 MG $42.298 J7517 MYCOPHENOLATE MOFETIL, ORAL 250 MG $0.887 J7518 MYCOPHENOLIC ACID, ORAL 180 MG $2.675 J7520 SIROLIMUS, ORAL 1 MG $7.462 J7525 TACROLIMUS, PARENTERAL 5 MG $187.831 J7527 EVEROLIMUS, ORAL 0.25 MG $8.349 J7605KO ARFORMOTEROL, INHALATION SOLUTION, FDA APPROVED FINAL PRODUCT, NON-COMPOUNDED, 15 MCG $9.460 J7606KO FORMOTEROL FUMARATE, INHALATION SOLUTION, FDA APPROVED FINAL PRODUCT, NON-COMPOUNDED, 20 MCG $10.316 J7608KO ACETYLCYSTEINE, INHALATION SOLUTION, FDA- APPROVED FINAL PRODUCT, NON-COMPOUNDED, 1 GM $5.474 J7611 ALBUTEROL, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED 1 MG THROUGH DME, CONCENTRATED FORM $0.143 J7612 LEVALBUTEROL, INHALATION SOLUTION, FDA- APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, CONCENTRATED FORM 0.5 MG $0.190 Copyright 2017 CGS Administrators, LLC. Page 2 of 6 12/272017

ALBUTEROL, INHALATION SOLUTION, FDA-APPROVED J7613KO FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED 1 MG THROUGH DME, UNIT DOSE $0.047 LEVALBUTEROL, INHALATION SOLUTION, FDA- J7614KO APPROVED FINAL PRODUCT, NON-COMPOUNDED, 0.5 MG ADMINISTERED THROUGH DME, UNIT DOSE $0.057 ALBUTEROL, UP TO 2.5 MG AND IPRATROPIUM BROMIDE, J7620 UP TO 0.5 MG, FDA-APPROVED FINAL PRODUCT, NON- 1 UNIT COMPOUNDED, ADMINISTERED THROUGH DME $0.116 BUDESONIDE, INHALATION SOLUTION, FDA-APPROVED J7626KO FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED UP TO 0.5 MG THROUGH DME, UNIT DOSE FORM $3.166 CROMOLYN SODIUM, INHALATION SOLUTION, FDA- J7631KO APPROVED FINAL PRODUCT, NON-COMPOUNDED, 10 MG $0.736 DORNASE ALPHA, INHALATION SOLUTION, FDA- J7639KO APPROVED FINAL PRODUCT, NON-COMPOUNDED, 1 MG $45.463 IPRATROPIUM BROMIDE, INHALATION SOLUTION, FDA- J7644KO APPROVED FINAL PRODUCT, NON-COMPOUNDED, 1 MG $0.218 METAPROTERENOL SULFATE, INHALATION SOLUTION, J7669KO FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, 10 MG TBD* TOBRAMYCIN, INHALATION SOLUTION, FDA-APPROVED J7682KO FINAL PRODUCT, NON-COMPOUNDED, UNIT DOSE 300 MG FORM, ADMINISTERED THROUGH DME $39.702 TREPROSTINIL, INHALATION SOLUTION, FDA-APPROVED J7686KO FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED 1.74 MG THROUGH DME, UNIT DOSE FORM $557.079 J8501 APREPITANT, ORAL 5 MG $6.678 J8520 CAPECITABINE, ORAL 150 MG $1.672 J8521 CAPECITABINE, ORAL $5.743 J8530 CYCLOPHOSPHAMIDE; ORAL 25 MG $3.428 J8540 DEXAMETHASONE, ORAL 0.25 MG $0.081 J8610 METHOTREXATE; ORAL 2.5 MG $0.336 J8650 NABILONE, ORAL 1 MG $38.195 J8655 NETUPITANT AND PALONOSETRON, ORAL 300 MG and 0.5 MG $398.829 J8670 ROLAPITANT, ORAL 1 MG $3.506 J9000 INJECTION, DOXORUBICIN HYDROCHLORIDE 10 MG $3.135 J9039 INJECTION, BLINATUMOMAB 1 MCG $107.741 J9040 INJECTION, BLEOMYCIN SULFATE 15 UNITS $26.988 J9065 INJECTION, CLADRIBINE 1 MG $21.180 J9100 INJECTION, CYTARABINE 100 MG $0.785 J9181 INJECTION, ETOPOSIDE 10 MG $0.609 J9190 INJECTION, FLUOROURACIL $1.518 J9200 INJECTION, FLOXURIDINE $62.845 J9208 INJECTION, IFOSFAMIDE 1 GM $26.467 J9355 INJECTION, TRASTUZUMAB 10 MG $100.652 J9360 INJECTION,VINBLASTINE SULFATE 1 MG $3.407 J9370 VINCRISTINE SULFATE 1 MG $4.767 Copyright 2017 CGS Administrators, LLC. Page 3 of 6 12/272017

Q0162 ONDANSETRON, ORAL, FDA APPROVED PRESCRIPTION ANTI-EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT THE TIME OF CHEMOTHERAPY TREATMENT, NOT TO EXCEED A 48 HOUR DOSAGE REGIMEN 1 MG $0.029 Q0163 DIPHENHYDRAMINE HYDROCHLORIDE, ORAL, FDA TO EXCEED A 48 HOUR DOSAGE REGIMEN 50 MG $0.266 Q0164 PROCHLORPERAZINE MALEATE, ORAL, FDA APPROVED A 48 HOUR DOSAGE REGIMEN 5MG $0.041 Q0166 Q0167 GRANISETRON HYDROCHLORIDE, ORAL, FDA TO EXCEED A 24 HOUR DOSAGE REGIMEN DRONABINOL, ORAL, FDA APPROVED PRESCRIPTION ANTI-EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT TIME OF CHEMOTHERAPY TREATMENT NOT TO EXCEED A 48 HOUR DOSAGE REGIMEN 1 MG 2.5 MG $2.000 $2.338 Q0169 PROMETHAZINE HYDROCHLORIDE, ORAL, FDA TO EXCEED A 48 HOUR DOSAGE REGIMEN 12.5 MG $0.023 Q0173 TRIMETHOBENZAMIDE HYDROCHLORIDE, ORAL, FDA TO EXCEED A 48 HOUR DOSAGE REGIMEN 250 MG TBD* Q0174 THIETHYLPERAZINE MALEATE, ORAL, FDA APPROVED A 48 HOUR DOSAGE REGIMEN 10 MG TBD* Copyright 2017 CGS Administrators, LLC. Page 4 of 6 12/272017

Q0175 PERPHENAZINE, ORAL, FDA APPROVED PRESCRIPTION ANTI-EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT TIME OF CHEMOTHERAPY TREATMENT NOT TO EXCEED A 48 HOUR DOSAGE REGIMEN 4 MG $1.467 Q0177 HYDROXYZINE PAMOATE, ORAL, FDA APPROVED A 48 HOUR DOSAGE REGIMEN 25 MG $0.140 Q0180 Q0510 Q0511 DOLASETRON MESYLATE, ORAL, FDA APPROVED A 24 HOUR DOSAGE REGIMEN PHARMACY SUPPLY FEE FOR INITIAL IMMUNOSUPPRESSIVE DRUG(S), FIRST MONTH FOLLOWING TRANSPLANT PHARMACY SUPPLY FEE FOR ORAL ANTI-CANCER, ORAL ANTI-EMETIC OR IMMUNOSUPPRESSIVE DRUG(S); FOR THE FIRST PRESCRIPTION IN A 30-DAY PERIOD 100 MG $101.236 $50.000 $24.000 Q0512 PHARMACY SUPPLY FEE FOR ORAL ANTI-CANCER, ORAL ANTI-EMETIC OR IMMUNOSUPPRESSIVE DRUG(S); FOR A SUBSEQUENT PRESCRIPTION IN A 30-DAY PERIOD $16.000 Q0513 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); PER 30 DAYS $33.000 Q0514 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); PER 90 DAYS $66.000 ILOPORST, INHALATION SOLUTION, FDA-APPROVED Q4074 FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED UP TO 20 MCG THROUGH DME, UNIT DOSE FORM $130.250 NDC number BUSULFAN, ORAL 2 MG $24.122 NDC number CAPECITABINE, ORAL 150 MG $1.672 NDC number CAPECITABINE, ORAL $5.743 NDC number CYCLOPHOSPHAMIDE, ORAL 25 MG $3.428 NDC number CYCLOPHOSPHAMIDE, ORAL 50 MG $6.856 NDC number ETOPOSIDE, ORAL 50 MG $73.777 NDC number FLUDARABINE PHOSPHATE, ORAL 10 MG TBD* NDC number MELPHALAN, ORAL 2 MG $11.724 NDC number METHOTREXATE, ORAL 2.5 MG $0.336 NDC number METHOTREXATE, ORAL 5 MG $0.672 NDC number METHOTREXATE, ORAL 7.5 MG $1.008 NDC number METHOTREXATE, ORAL 10 MG $1.344 NDC number METHOTREXATE, ORAL 15 MG $2.016 NDC number TEMOZOLOMIDE, ORAL 5 MG $1.025 NDC number TEMOZOLOMIDE, ORAL 20 MG $4.100 NDC number TEMOZOLOMIDE, ORAL 100 MG $20.500 Copyright 2017 CGS Administrators, LLC. Page 5 of 6 12/272017

NDC number TEMOZOLOMIDE, ORAL 140 MG $28.700 NDC number TEMOZOLOMIDE, ORAL 180 MG $36.900 NDC number TEMOZOLOMIDE, ORAL 250 MG $51.250 NDC number TOPOTECAN, ORAL 0.25 MG $103.677 *To Be Developed (TBD) indicates the claim will be developed for an invoice on the drug billed. ** Effective January 1, 2017, the HCPCS code with the JB modifier no longer has a different fee than the HCPCS code without the JB modifier. Copyright 2017 CGS Administrators, LLC. Page 6 of 6 12/272017